| Improvements in renal osteodystrophy in patients treated with lanthanum carbonate for two years. | |
| | |
MedLine Citation:
|
PMID: 18826853 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
AIMS: To investigate the evolution of renal osteodystrophy in patients on maintenance dialysis, treated with lanthanum carbonate (LC) vs. standard phosphate-binder therapy (Stx). MATERIALS AND METHODS: This was a 2-year, randomized, prospective, open-label study during which patients on dialysis received LC titrated to a maximum of 3,000 mg/day or their previous phosphate binder treatment with the aim to achieve target phosphorus levels of < or = 5.9 mg/dl. Paired bone biopsy samples for histomorphometric analysis were available at baseline and 1 year (LC 32, Stx 33), and at baseline and 2 years (LC 32, Stx 24). RESULTS: With similar phosphorus control, Stx was associated with numerically higher serum calcium levels at most visits. Results of osteocalcin and bone-specific alkaline phosphatase in LC patients were higher throughout the study and correlated with parameters of bone formation; however, the differences were not significant. Histological changes in bone turnover and volume were analyzed with respect to normal ranges. There was an improvement in bone turnover in the LC group, which was significant in the 1-year group, and an improvement in bone volume which was significant in the 2-year group. No significant changes in bone turnover or bone volume were observed in the Stx groups. In the 2-year LC group, 1 patient had osteomalacia at baseline and end of therapy, and a mineralization defect developed in 2 other patients. Several possible factors for a mineralization defect were present in these patients, but no single cause could be clearly identified. Histomorphometric parameters of bone, including formation and mineralization, did not correlate with bone lanthanum. No mineralization defect was observed in the Stx groups. CONCLUSION: These findings show that similar phosphorus control with Stx and LC results in higher bone turnover after 1 year and higher bone volume after 2 years with LC. |
| | |
Authors:
|
H H Malluche; G A Siami; C Swanepoel; G H Wang; H Mawad; S Confer; M Smith; R D Pratt; M-C Monier-Faugere; |
Related Documents
:
|
10913923 - Serum type i collagen breakdown product (serum ctx) predicts hip fracture risk in elder... 12928833 - Changes in bone turnover markers during 14-day 6 degrees head-down bed rest. 8858043 - Open knee dislocation associated with vascular injury successfully salvaged by primary ... |
Publication Detail:
|
Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Clinical nephrology Volume: 70 ISSN: 0301-0430 ISO Abbreviation: Clin. Nephrol. Publication Date: 2008 Oct |
Date Detail:
|
Created Date: 2008-10-01 Completed Date: 2009-01-27 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0364441 Medline TA: Clin Nephrol Country: Germany |
Other Details:
|
Languages: eng Pagination: 284-95 Citation Subset: IM |
Affiliation:
|
Division of Nephrology, Bone and Mineral Metabolism, University of Kentucky, Lexington, KY 40536, USA. hhmall@uky.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Analysis of Variance Biological Markers / blood Bone Remodeling / drug effects Calcium / blood Female Humans Lanthanum / therapeutic use* Male Middle Aged Parathyroid Hormone / blood Phosphorus / blood Prospective Studies Renal Dialysis Renal Osteodystrophy / drug therapy* Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Biological Markers; 0/Parathyroid Hormone; 0/lanthanum carbonate; 7439-91-0/Lanthanum; 7440-70-2/Calcium; 7723-14-0/Phosphorus |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Vitamin D receptor ligand therapy in chronic kidney disease.
Next Document: Bone histomorphometry and biochemical markers of bone turnover in patients with chronic kidney disea...